Combination Treatment for Myelofibrosis Shows Potential in Early Trial
source: pixabay.com

Combination Treatment for Myelofibrosis Shows Potential in Early Trial

According to a story from Targeted Oncology, findings from a recent phase 1 trial have discovered a new potential treatment for myelofibrosis. The study combined two different drugs: panobinostat (marketed…

Continue Reading Combination Treatment for Myelofibrosis Shows Potential in Early Trial
Medical College of Wisconsin Creates ER Alternative for Treating Myeloproliferative Neoplasms and Other Cancers
source: pixabay.com

Medical College of Wisconsin Creates ER Alternative for Treating Myeloproliferative Neoplasms and Other Cancers

Cancer patients often face adverse effects from their treatment. These effects typically need to be addressed by a doctor, whether they're nausea, rashes, or anything else. The issue is that…

Continue Reading Medical College of Wisconsin Creates ER Alternative for Treating Myeloproliferative Neoplasms and Other Cancers

Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis

Hereditary Hemochromatosis Hereditary hemochromatosis (HH) is a rare disease caused by hepcidin deficiency or hepcidin insensitivity. Hepcidin naturally regulates iron absorption/distribution in the body. Without hepcidin, HH patients suffer from…

Continue Reading Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis
Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
qimono / Pixabay

Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study

According to a publication from Oncology Nurse Advisor, a study of 109 patients with myeloproliferative neoplasms (certain types of blood cancers) found that mortality rates for younger patients were similar…

Continue Reading Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
Olympian Scott Hamilton Honors Group of People Who Serve Rare Blood Cancer Community
Source: Pixabay.com

Olympian Scott Hamilton Honors Group of People Who Serve Rare Blood Cancer Community

Olympian skater Scott Hamilton was the keynote speaker at the CURE media group's sixth annual myeloproliferative neoplasm (MPN) Heroes celebration, honoring nine individuals who have also dedicated themselves to improving the lives…

Continue Reading Olympian Scott Hamilton Honors Group of People Who Serve Rare Blood Cancer Community
Study Shows the Most Effective Treatments for Polycythemia Vera are Under-prescribed
source: pixabay.com

Study Shows the Most Effective Treatments for Polycythemia Vera are Under-prescribed

Polycythemia Vera or PV, is a rare blood cancer. It's caused by a mutation which results in the overproduction of red blood cells. Too many blood cells significantly increases your…

Continue Reading Study Shows the Most Effective Treatments for Polycythemia Vera are Under-prescribed
Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
stevepb / Pixabay

Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released

The drug Jakavi (ruxolitinib) is being investigated as a possible treatment for polycythemia vera (PV) and myelofibrosis. Results from studies into this were presented by Novartis at the 23rd Congress of…

Continue Reading Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
Close Menu